Finance

Lists
GLENMARK:NSE
Glenmark Pharmaceuticals Ltd
₹2,646.10
+1.16%
(+30.30) 1D
Nov 18, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLENMARK...
Open
₹2,663.60
High
₹2,691.50
Low
₹2,625.10
Mkt. cap
746.79B
Avg. vol.
786.54K
Volume
1.09M
Dividend
0.19%
Quarterly dividend
₹1.25
Ex-dividend date
Oct 3, 2025
P/E ratio
41.55
52-wk high
₹2,714.00
52-wk low
₹1,818.00
EPS
₹63.68
Shares outstanding
0.00
No. of employees
17K
Open
₹2,663.60
High
₹2,691.50
Low
₹2,625.10
Mkt. cap
746.79B
Avg. vol.
786.54K
Volume
1.09M
Dividend
0.19%
Quarterly dividend
₹1.25
Ex-dividend date
Oct 3, 2025
P/E ratio
41.55
52-wk high
₹2,714.00
52-wk low
₹1,818.00
EPS
₹63.68
Shares outstanding
0.00
No. of employees
17K
News stories
From web sources and news partners
Profile
Glenmark Pharmaceuticals Limited is an Indian pharmaceutical company with its headquarters in Mumbai. It was founded 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, and its shares are listed on the Bombay Stock Exchange and the National Stock Exchange of India. The company produces and distributes medicines in more than 80 countries, with operations mainly in India, North America, and Europe. It had about 17,000 employees as of March 2026. Its name comes from Saldanha's sons, Glenn and Mark. Glenmark began developing proprietary medicines in the mid-2010s. In 2025, its research arm, Ichnos Glenmark Innovation, licensed ISB 2001, an investigational treatment for multiple myeloma, to AbbVie for an upfront payment of $700 million. The U.S. Food and Drug Administration has issued warning letters to several of the company's plants in India and the United States. Wikipedia
About Glenmark Pharmaceuticals Ltd
CEO-
Employees16.9K
FoundedNov 18, 1977
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Last report
Nov 6, 2026
Fiscal period
Q2 2027
₹17.18 / ₹15.60
+10.12%beat
Revenue / Est. (INR)
42.47B / 41.10B
+3.35%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
39.01B
38.31B
40.18B
42.47B
Cost of goods sold
12.95B
13.65B
12.46B
13.06B
Cost of revenue
12.95B
13.65B
12.46B
13.06B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.41B
16.49B
9.35B
10.28B
Operating expense
18.90B
17.91B
21.41B
22.58B
Total operating expenses
31.85B
31.56B
33.87B
35.64B
Operating income
7.15B
6.75B
6.32B
6.83B
Other non operating income
444.65M
-2.72B
657.64M
25.41M
EBT including unusual items
5.34B
3.88B
6.43B
3.38B
EBT excluding unusual items
7.18B
7.61B
6.43B
6.22B
Income tax expense
1.31B
864.49M
1.61B
744.58M
Effective tax rate
24.49%
22.29%
24.96%
22.01%
Other operating expenses
8.94B
-55.65M
10.33B
10.50B
Net income
4.03B
3.01B
4.83B
2.64B
Net profit margin
10.34%
7.87%
12.02%
6.21%
Earnings per share
19.21
20.96
17.11
17.18
Interest and investment income
-
413.36M
-
-
Interest expense
-414.32M
-426.04M
-539.97M
-637.67M
Net interest expenses
-414.32M
-12.68M
-539.97M
-637.67M
Depreciation and amortization charges
1.54B
1.48B
1.73B
1.80B
EBITDA
7.80B
7.80B
7.75B
8.60B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps